Saltar al contenido
Merck

Crmp4 deletion promotes recovery from spinal cord injury by neuroprotection and limited scar formation.

Scientific reports (2015-02-06)
Jun Nagai, Yoshiteru Kitamura, Kazuki Owada, Naoya Yamashita, Kohtaro Takei, Yoshio Goshima, Toshio Ohshima
RESUMEN

Axonal outgrowth inhibitors and scar formation are two major obstacles to central nervous system (CNS) repair. No target molecule that regulates both axonal growth and scarring has been identified. Here we identified collapsin response mediator protein 4 (CRMP4), a common mediator of inhibitory signals after neural injury, as a crucial factor that contributes to both axonal growth inhibition and scarring after spinal cord injury (SCI). We found increases in the inhibitory and toxic forms of CRMP4 in injured spinal cord. Notably, CRMP4 expression was evident in inflammatory cells as well as in neurons after spinal cord transection. Crmp4-/- mice displayed neuroprotection against SCI and reductions in inflammatory response and scar formation. This permissive environment for axonal growth due to CRMP4 deletion restored locomotor activity at an unusually early phase of healing. These results suggest that deletion of CRMP4 is a unique therapeutic strategy that overcomes two obstacles to CNS repair after SCI.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-proteína gliofibrilar ácida (GFAP) monoclonal antibody produced in mouse, clone G-A-5, ascites fluid
Sigma-Aldrich
Anticuerpo anti-MAP2, clon AP20, clone AP20, Chemicon®, from mouse
Sigma-Aldrich
Anti-Tumor Necrosis Factor-α Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anticuerpo anti-macrófagos/ granulocitos, clon OX-41, clone OX-41, Chemicon®, from mouse
Sigma-Aldrich
Anti-TUC-4 Protein Antibody, serum, Chemicon®